Noticias

Noticias

  • Título: TriVascular Technologies, Inc. Announces the Closing of Its Initial Public Offering
  • Fecha: 22-04-2014

  • SANTA ROSA, Calif., April 22, 2014 (GLOBE NEWSWIRE) -- TriVascular Technologies, Inc. (Nasdaq:TRIV), manufacturer of the Ovation Prime™ Abdominal Stent Graft System, today announced the closing of its initial public offering of 7,475,000 shares of its common stock at a public offering price of $12.00 per share, including 975,000 shares sold pursuant to the underwriter's option to purchase additional shares. The company's shares began trading on The NASDAQ Global Select Market on April 16, 2014 under the ticker symbol 'TRIV.'

    J.P. Morgan Securities LLC and Credit Suisse Securities (USA) LLC acted as joint book-running managers for the offering. Canaccord Genuity Inc. and Stifel, Nicolaus & Company, Incorporated acted as co-managers.

    A registration statement relating to the securities being sold in this offering was declared effective by the Securities and Exchange Commission on April 15, 2014. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.

    The offering was made only by means of a prospectus. Copies of the final prospectus may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204, or from Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, by telephone at (800) 221-1037 or by email at newyork.prospectus@credit-suisse.com.



  • Fuente: endovascular.es